Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:40 UTC |
---|
HMDB ID | HMDB0014574 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Cefpiramide |
---|
Description | Cefpiramide, also known as CPM or SM-1652, belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. Cefpiramide is a drug which is used for treatment of severe infections caused by susceptible bacteria such as p. aeruginosa. Based on a literature review a significant number of articles have been published on Cefpiramide. |
---|
Structure | [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1 |
---|
Synonyms | Value | Source |
---|
Cefpiramido | ChEBI | Cefpiramidum | ChEBI | CPM | Kegg | SM-1652 | HMDB | Cefpiramide sodium | HMDB | Sumcefal | HMDB | Cefpiramide, sodium salt | HMDB |
|
---|
Chemical Formula | C25H24N8O7S2 |
---|
Average Molecular Weight | 612.637 |
---|
Monoisotopic Molecular Weight | 612.120936542 |
---|
IUPAC Name | (6R,7R)-7-[(2R)-2-[(4-hydroxy-6-methylpyridin-3-yl)formamido]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
---|
Traditional Name | cefpiramido |
---|
CAS Registry Number | 70797-11-4 |
---|
SMILES | [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O |
---|
InChI Identifier | InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1 |
---|
InChI Key | PWAUCHMQEXVFJR-PMAPCBKXSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Peptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha peptide
- Cephalosporin
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid amide
- N-substituted-alpha-amino acid
- Alpha-amino acid or derivatives
- Phenylacetamide
- Cephem
- Nicotinamide
- Pyridine carboxylic acid or derivatives
- Aryl thioether
- Dihydropyridine
- Alkylarylthioether
- Methylpyridine
- Phenol
- 1-hydroxy-2-unsubstituted benzenoid
- Hydropyridine
- Benzenoid
- Meta-thiazine
- Monocyclic benzene moiety
- Pyridine
- Heteroaromatic compound
- Vinylogous amide
- Beta-lactam
- Azole
- Tetrazole
- Tertiary carboxylic acid amide
- Azetidine
- Cyclic ketone
- Carboxamide group
- Secondary carboxylic acid amide
- Lactam
- Organoheterocyclic compound
- Azacycle
- Dialkylthioether
- Sulfenyl compound
- Hemithioaminal
- Thioether
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Carbonyl group
- Organic oxide
- Organosulfur compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.067 g/L | Not Available | LogP | -0.9 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Cefpiramide,1TMS,isomer #1 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5456.4 | Semi standard non polar | 33892256 | Cefpiramide,1TMS,isomer #2 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5530.7 | Semi standard non polar | 33892256 | Cefpiramide,1TMS,isomer #3 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5434.1 | Semi standard non polar | 33892256 | Cefpiramide,1TMS,isomer #4 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5328.4 | Semi standard non polar | 33892256 | Cefpiramide,1TMS,isomer #5 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 5314.0 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #1 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5309.2 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #10 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 5073.2 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #2 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5382.9 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #3 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 5179.9 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #4 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5194.8 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #5 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5395.0 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #6 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N1 | 5225.6 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #7 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5268.7 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #8 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 5155.1 | Semi standard non polar | 33892256 | Cefpiramide,2TMS,isomer #9 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5157.5 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #1 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5328.2 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #10 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 4951.1 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #2 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 5085.0 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #3 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5083.1 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #4 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N1 | 5147.0 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #5 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5180.7 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #6 | CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N1 | 4994.0 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #7 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N1 | 5134.6 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #8 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N1 | 5153.7 | Semi standard non polar | 33892256 | Cefpiramide,3TMS,isomer #9 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N1 | 5039.8 | Semi standard non polar | 33892256 | Cefpiramide,1TBDMS,isomer #1 | CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5648.3 | Semi standard non polar | 33892256 | Cefpiramide,1TBDMS,isomer #2 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N1 | 5735.4 | Semi standard non polar | 33892256 | Cefpiramide,1TBDMS,isomer #3 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5690.1 | Semi standard non polar | 33892256 | Cefpiramide,1TBDMS,isomer #4 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5622.6 | Semi standard non polar | 33892256 | Cefpiramide,1TBDMS,isomer #5 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N1 | 5627.0 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #1 | CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N1 | 5741.9 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #10 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N1 | 5548.3 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #2 | CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N1 | 5794.4 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #3 | CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N1 | 5642.2 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #4 | CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5626.7 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #5 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N1 | 5829.8 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #6 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C=N1 | 5706.8 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #7 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N1 | 5717.7 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #8 | CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N1 | 5661.1 | Semi standard non polar | 33892256 | Cefpiramide,2TBDMS,isomer #9 | CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N1 | 5630.4 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-0190100000-3a610343fcd1d398dda6 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (1 TMS) - 70eV, Positive | splash10-0ap0-6690032000-262799ec7d036af94689 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_5) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_7) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_8) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_9) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_10) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_5) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_6) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_7) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_8) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_9) - 70eV, Positive | Not Available | 2021-10-16 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 10V, Positive-QTOF | splash10-05i3-1095151000-92abd90f62711e4b473c | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 20V, Positive-QTOF | splash10-0abi-2493100000-ef6a3fd20e699b3093ff | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 40V, Positive-QTOF | splash10-0abi-1590000000-e6b1c4b8020103cdfb97 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 10V, Negative-QTOF | splash10-014l-1619041000-aa3e6e4912cbf04bb33d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 20V, Negative-QTOF | splash10-0aor-9612000000-50a4d1c82eae2b589f0a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 40V, Negative-QTOF | splash10-0aou-9821000000-cd698beec1f947a53c9c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 10V, Positive-QTOF | splash10-03di-0458904000-3032d4ddc3c8f7b51cff | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 20V, Positive-QTOF | splash10-052r-1976121000-db6d805969c93a849ecb | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 40V, Positive-QTOF | splash10-000i-1922120000-98285a42e6de6a4f713e | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 10V, Negative-QTOF | splash10-004i-0001092000-141daf7cdb4006d57125 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 20V, Negative-QTOF | splash10-06e9-1960021000-bb13589005f1776e4ca8 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cefpiramide 40V, Negative-QTOF | splash10-05mo-9810020000-c7546729a2f25176b49a | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|
General References | - Sampi K, Hattori M: [Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study]. Gan To Kagaku Ryoho. 1992 Aug;19(9):1315-20. [PubMed:1503486 ]
- Iakovlev VP, Vishnevskii VA, Khlebnikov EP, Khadin IM, Plavlova MV, Elagina LV, Izotova GN: [Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery]. Antibiot Khimioter. 1995 Sep;40(9):30-4. [PubMed:8651827 ]
- Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M: In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. J Infect Chemother. 2000 Jun;6(2):81-5. [PubMed:11810540 ]
|
---|